This paper develops an oligopoly model in which firms first choose capacity and then compete prices a series of advance-purchase markets.

This paper studies price discrimination in forty emerging markets for forty-nine generic drugs for the therapeutic areas of cardiovascular diseases and infectious diseases. This paper studies how the age of a drug and how income distribution in a country affect the price discrimination of that drug in the country. Price data comes from the World Health Organization and Health Action Internation...